- Noteworthy events during the week of December 16 - 22 for healthcare investors.
-
MONDAY (12/17): Innovate Biopharmaceuticals (NASDAQ:INNT): Investor update on capital plan for celiac disease clinical development and NASH development strategy.
-
Achillion Pharmaceuticals (NASDAQ:ACHN): Webcast of 2019 development plans, interim Phase 2 data in PNH and Phase 1 data on next-gen factor D inhibitors.
-
TUESDAY (11/18): FDA action date for ADMA Biologics' (NASDAQ:ADMA) BLA amendment for Bivigam.
-
WEDNESDAY (11/19): Eli Lilly (NYSE:LLY): Investor event reviewing strategic goals and 2019 outlook.
- FDA action date for Novartis' (NYSE:NVS) Promacta for first-line severe aplastic anemia.
- FDA action date for Sage Therapeutics' (NASDAQ:SAGE) brexanolone for postpartum depression (date extended to March 19, 2019 to allow for review of REMS program).
-
THURSDAY (12/20): FDA action date for Jazz Pharmaceuticals' (NASDAQ:JAZZ) solriamfetol for excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
-
Health Insurance Innovations (NASDAQ:HIIQ): Analyst & Investor Day.
-
Walgreens Boots Alliance (NASDAQ:WBA): Fiscal Q1 earnings release.
-
FRIDAY (12/21): FDA action date for Shire's (NASDAQ:SHPG) prucalopride for chronic idiopathic constipation.
-
SATURDAY (12/22): FDA action date for Shire's Calaspargase Pegol (Cal-PEG) for acute lymphoblastic leukemia.